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Available online 24 February 2016Background: Here we describe the determination of upper reference limits (URL) for galectin-3, high-sensitivity
cardiac troponin I (hs-cTnI) and high-sensitivity cardiac troponin T (hs-cTnT) in a single cohort of healthy blood
donors using routine assays.
Methods: For this reference value study, we used a cohort of 402 consecutive blood donors (64% were male and
36%were female). Themedian individuals' agewas 35.0 years (range, 18.0–64.4). Individuals of this reference pop-
ulation were free of cardiovascular disease, diabetes mellitus, renal disease, cancer, current infection and chronic
inﬂammatory disease. Plasma concentrations of galectin-3 were measured with the “routine Galectin-3” assay
(Abbott Diagnostics), of hs-cTnI with the “STAT High Sensitive Troponin-I” assay (Abbott Diagnostics), and
of hs-cTnT with the “Troponin T hs” assay (Roche Diagnostics). URLs were calculated by using a non-parametric
percentile method.
Results: The 97.5th percentile URL for galectin-3was 16 ng/mL inmales and 17 ng/mL in females; the 99th percen-
tile URL for hs-cTnI was 39 ng/L in males and 24 ng/L in females; and the 99th percentile URL for hs-cTnT was
14 ng/L in males and 11 ng/L in females. Those individuals with hs-cTnI values ≥15 ng/L (n = 8) were different
from those individuals with hs-cTnT values ≥10 ng/L (n = 7). Of the 402 individuals, none had galectin-3 values
below the limit of detection (LOD, b1.0 ng/mL), 290 (72%) had hs-cTnI values below the LOD (i.e., 1.9 ng/L), and
359 (89%) had hs-cTnT values below the LOD (i.e., 5.0 ng/L).
Conclusion: Plasma concentrations of galectin-3, hs-cTnI and hs-cTnT and corresponding 99th percentile URLs
were rather low in our cohort of healthy blood donors comparedwith previously published data. In our reference
population, analyte plasma concentrations above the LOD were detectable in 100% of the individuals with the
Abbott galectin-3 assay, but only in less than 50% for both the Abbott hs-cTnI assay and the Roche hs-cTnT assay.







Upper reference limits1. Introduction
Galectin-3 is a unique member of chimera type galectins and is in-
volved in a large number of disease processes [1]. Galectin-3 partici-
pates in cell adhesion, activation, proliferation, apoptosis as well as
cell migration [1,2]. It plays an important role in cancer [2] and inﬂam-
mation [1,3]. Even in the pathophysiology of cardiac disease, galectin-3
is thought to play a biological role through inﬂammation and ﬁbrosis [4,
5]. As a consequence, the biomarker galectin-3 has been included in the
2013 ACCF/AHA guideline for additive risk stratiﬁcation of patients with
acute and chronic heart failure [6].
To date, only few and conﬂicting data have been published on upper
reference limits (URL) of circulating galectin-3. Thus, the aim of thisry Medicine, Konventhospital
ria.
).
. This is an open access article understudy was to establish reference values for galectin-3. As reference
values for cardiac troponins are still under debate [7–14], we addition-
ally aimed at evaluating URLs of high-sensitivity cardiac troponin I
(hs-cTnI) and high-sensitivity cardiac troponin T (hs-cTnT) in a single
cohort of healthy blood donors.
2. Materials and methods
2.1. Study protocol
For the present reference value study, we used a cohort of 559 con-
secutive Caucasian blood donors as described previously [15]. This co-
hort was recruited at the Red Cross organization in Linz, Austria, in
2008. All study participants completed questionnaires detailing their
medical histories andmedications in order to conﬁrm their good health
before blood collection according to Austrian laws. This healthy refer-
ence population was, thus, deﬁned as individuals who were free ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
20 T. Mueller et al. / Clinica Chimica Acta 456 (2016) 19–23cardiovascular disease (no arterial hypertension, no history of any car-
diac disease, cardiac treatment or cardiac intervention, no history of
stroke or transient ischemic attack, no history of peripheral artery dis-
ease, no history venous thromboembolism). Additional exclusion
criteria included, e.g., pregnancy, age ≥ 65.0 years, history of diabetes
mellitus, renal disease and cancer, or current infection and any chronic
inﬂammatory disease. The study protocol was approved by the local
ethics committee in accordance with the Declaration of Helsinki, and
all study participants gave informed consent.
Blood was obtained by conventional venipuncture avoiding venous
stasis. Using VACUETTE® polyethylene terephthalate glycol (PET)
blood collection tubes (Greiner Bio-One, Kremsmuenster, Austria),
EDTA anticoagulated blood and serum were collected. C-reactive
protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), creatinine, and
B-type natriuretic peptide (BNP) were quantiﬁed within 4 h of blood
collection in all study participants from fresh samples. In addition,
serum and plasma samples were frozen in several aliquots at−80 °C
within 4 h. One of these frozen aliquots from each study participant
was thawed to determine hs-cTnT, another aliquot to determine hs-
cTnI, and a third aliquot to determine galectin-3. Of note, each of the al-
iquots was subjected to one freeze–thaw cycle only.
Criteria for the 559 blood donors to be included into the present
reference value study were CRP serum concentrations ≤1.0 mg/dL,
PCT serum concentrations ≤0.5 ng/mL, IL-6 serum concentrations
≤15.0 pg/mL, and BNP plasma concentrations ≤100 pg/mL (which are
reference values used in our laboratory and are also generally accepted
URLs for those same analytes as described in the literature).
Data were statistically analyzed with the SPSS 13.0 software (SPSS
Inc., Chicago, IL, USA) and the MedCalc 13.0.0.0 package (MedCalc
Software, Mariakerke, Belgium). Comparisons of continuous variables
(i.e., galectin-3, hs-cTnI and hs-cTnT) between different reference
value groups were performedwith the non-parametric Mann–Whitney
U test or the non-parametric Kruskal–Wallis test, as appropriate. Ob-
tained p values were not adjusted for multiple comparisons and are
therefore descriptive only. URLs were calculated by using a right-sided
non-parametric percentilemethod according to the Clinical and Labora-
tory Standards Institute (CLSI) guideline EP28-A3c [16]. Ninety percent
conﬁdence intervals (CI) were provided for the URLs, if possible.2.2. Galectin-3, hs-cTnI and hs-cTnT measurements
In December 2009, we measured hs-cTnT plasma concentrations of
the blood donors in one batch with the “Troponin T hs” assay (Roche
Diagnostics, Mannheim, Germany, reagent lot number 156 593-01)
[17,18] on a Modular platform because we started to use this assay at
this time in clinical routine in our hospital. As stated in the package in-
sert, this assay has a measurement range of 3.0–10,000 ng/L (deﬁned as
limit of blank to the maximum value of themaster curve) and a limit of
detection of 5.0 ng/L. Accordingly, hs-cTnT concentrations ≤5.0 ng/L
were reported as 5.0 ng/L in thepresentwork. Themanufacturer reports
a 10% coefﬁcient of variation at a hs-cTnT concentration of 13.0 ng/L
(i.e., limit of quantiﬁcation). We conﬁrmed all results with plasma con-
centrations N15 ng/L by a second measurement; no testing for
heterophilic antibodies was performed in these samples.Table 1
Analyte concentrations of the entire reference value cohort (n = 528) according to renal funct
Analyte Individuals with eGFR N90 mL/min/1.73 m2
(n = 402)
Galectin-3 [ng/mL] 10.7 (range, 5.0–21.9; 25th–75th percentiles, 9.3–12.4)
hs-cTnI [ng/L] 1.9 (range, 1.9–101.1; 25th–75th percentiles, 1.9–2.0)
hs-cTnT [ng/L] 5.0 (range, 5.0–20.1; 25th–75th percentiles, 5.0–5.0)
Abbreviations: hs-cTnI, high-sensitivity cardiac troponin I (Abbott); hs-cTnT, high-sensitivity c
Data are presented as median (range; 25th–75th percentiles). Difference of the analyte concen
were not corrected for multiple comparisons).In February 2013, hs-cTnI plasma concentrations of the blood donors
were measured in one batch with the “STAT High Sensitive Troponin-I”
assay (Abbott Diagnostics, Vienna, Austria, reagent lot number
23911JN00) [18,19] on an ARCHITECT I2000SR analyzer because in
2013 we switched to this assay for clinical routine use in our hospital.
As described in the package insert, this assay has a limit of blank of
0.7–1.3 ng/L, a limit of detection of 1.1–1.9 ng/L, and a measurement
range up to 50,000 ng/L. Thus, we decided to report observed hs-cTnI
concentrations ≤1.9 ng/L as 1.9 ng/L in this work. The manufacturer
claims a 10% coefﬁcient of variation at an hs-cTnI concentration of
4.0–10.0 ng/L (i.e., limit of quantiﬁcation). We conﬁrmed all results
with plasma concentrations N25 ng/L by a second measurement; no
testing for heterophilic antibodies was performed in these samples.
In November 2015, wemeasured galectin-3 plasma concentrations of
the blood donors in one batchwith the “routine Galectin-3” assay (Abbott
Diagnostics, Vienna, Austria, reagent lot number 48441M500) [20,21] on
an ARCHITECT I2000SR analyzer. According to the package insert this
assay has a measurement range of 4–114 ng/mL, and the limit of
detection is claimed to be b1.0 ng/mL by themanufacturer. As previously
reported [22], the Abbott galectin-3 assay has a total coefﬁcient of varia-
tion ofb5.0% for analyte concentrations N16ng/mL, and themanufacturer
describes a 10% coefﬁcient of variation at galectin-3 concentrations of
b4.0 ng/mL (i.e., limit of quantiﬁcation). We conﬁrmed all results with
plasma concentrations N20 ng/mL by a second measurement.
2.3. Further biochemical analyses
Serum concentrations of CRP were measured with the standard
laboratory method Tina-quant CRP (Latex) (Roche Diagnostics,
Mannheim, Germany), a particle-enhanced immunoturbidimetric
assay, processed on a Modular platform. PCT serum concentrations
were determined with an immunoﬂuorescent assay by using the
B.R.A.H.M.S. PCT assay (B.R.A.H.M.S. AG, Hennigsdorf, Germany) on
the KRYPTOR analyzer. Serum concentrations of IL-6 were measured
with a solid-phase, enzyme-labeled, chemiluminescent sequential
immunometric assay on an IMMULITE 2000 instrument (Siemens
Medical Solutions Diagnostics, Vienna, Austria). Creatinine serum con-
centrations were measured by a kinetic colorimetric assay according
to the Jaffé method (calibrators IDMS traceable; Roche Diagnostics,
Mannheim, Germany) on a Modular platform. Estimated glomerular
ﬁltration rate (eGFR) was calculated according to the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation [23]. Plasma
BNP concentrations were measured by using the ARCHITECT BNP
assay (Abbott Diagnostics, Vienna, Austria) which is a chemilumines-
cent microparticle immunoassay on an ARCHITECT I2000SR analyzer.
3. Results
Of the 559 blood donors recruited for establishing reference values,
31 did not fulﬁll the inclusion criteria and, thus, 528 were ﬁnally en-
rolled into this reference value study for determining upper reference
limits of galectin-3, hs-cTnI and hs-cTnT. Of the 528 individuals, 338
(64%)weremale and 190 (36%)were female. Biomarker concentrations
of all three analytes differed signiﬁcantly between male and female in-
dividuals (Mann–Whitney-U tests for each analyte, p ≤ 0.001). Inion.
Individuals with eGFR b90 mL/min/1.73 m2
(n = 126)
p value
12.1 (range, 6.0–24.4; 25th–75th percentiles, 10.2–14.1) b0.001
1.9 (range, 1.9–48.7; 25th–75th percentiles, 1.9–2.5) 0.005
5.0 (range, 5.0–25.3; 25th–75th percentiles, 5.0–5.2) b0.001
ardiac troponin T (Roche).
trations of both groups was calculated with Mann–Whitney-U tests (two-sided p values
Fig. 1. Distribution of (A) galectin-3; (B) hs-cTnI; and (C) hs-cTnT plasma concentrations
in the reference value cohort according to age groups. In each age group all data were
plotted as open squares (male individuals) or as open circles (female individuals), and
the horizontal lines represent the median analyte concentrations for males and females
of each age group. Abbreviations: hs-cTnI, high-sensitivity cardiac troponin I (Abbott);
hs-cTnT, high-sensitivity cardiac troponin T (Roche).
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function, thosewith an eGFR N90mL/min/1.73m2 did have signiﬁcantly
different galectin-3, hs-TnI and hs-TnT plasma concentrations com-
pared to those with an eGFR b90 mL/min/1.73 m2 (Mann–Whitney-U
tests for each analyte, p ≤ 0.005). Analyte concentrations of the entire
reference value cohort (n = 528) according to renal function are
shown in Table 1.
Thus, we decided to calculate sex-speciﬁc upper reference limits by
excluding those individuals with an eGFR b90 mL/min/1.73 m2. As a
consequence, we had 402 individuals with an eGFR N90 mL/min/
1.73 m2 for our present evaluation; 259 were male (64%) and 143 fe-
male (36%). The median individuals' age was 35.0 years (range, 18.0–
64.4, 25th–75th percentiles, 25.9–45.1), and the median individuals'
body mass index was 24.5 kg/m2 (range, 17.3–38.4, 25th–75th percen-
tiles, 22.3–27.2). The distributions of galectin-3, hs-cTnI and hs-cTnT
plasma concentrations across different age groups are depicted in
Fig. 1 for male and female individuals separately. The results of our ref-
erence value calculations are detailed in Table 2. Because it has been
posed that the future metric for cardiac troponins may shift from the
99th percentile to the more conventional 97.5th percentile as used in
laboratorymedicine formost analytes [10], we decided to report several
measures of distribution for galectin-3, hs-cTnI and hs-cTnT.
The 97.5th percentile URL for galectin-3 was 16 ng/mL in male and
17 ng/mL in female individuals; the 99th percentile URL for cTnI was
39 ng/L inmale and 24 ng/L in female individuals; and the 99th percen-
tile URL for cTnTwas 14 ng/L in male and 11 ng/L in female individuals.
For our reference value analyses, we did not exclude any potential out-
liers because those individuals with hs-cTnI plasma concentrations
≥15 ng/L (n = 8) were different from those individuals with hs-cTnT
plasma concentrations ≥10 ng/L (n = 7); in addition there was no
overlap of those individuals with galectin-3 plasma concentrations
≥16 ng/mL (n = 12) with the individuals of the former two groups.
Of the 402 individuals of the present evaluation, none had galectin-3
plasma concentrations below the limit of detection of this assay (limit of
detection of b1.0 ng/mL for this assay, lowest value of 5.0 ng/mL in this
reference value cohort). In contrast, 290 (72%) had hs-cTnI plasma con-
centrations ≤1.9 ng/L (i.e., limit of detection of the Abbott assay), and
359 (89%)hadhs-cTnTplasma concentrations≤5.0 ng/L (i.e., limit of de-
tection of the Roche assay).
The distribution of analyte concentrations across different age
groups indicated a rather weak but statistically signiﬁcant association
of galectin-3 plasma concentrations with age groups (Kruskal–Wallis
tests, p = 0.008 for male and p = 0.006 for female individuals) but
a much smaller phenomenon for hs-cTnI plasma concentrations
(Kruskal–Wallis tests, p = 0.009 for male and p = 0.186 for female in-
dividuals) and for hs-cTnT plasma concentrations (Kruskal–Wallis tests,
p = 0.106 for male and p = 0.388 for female individuals).
4. Discussion
To date, two studies evaluating reference values for galectin-3 in
adults using the Abbott assay have been published, however, with con-
ﬂicting results [20,21]. La'ulu et al. reported 97.5th percentile URLs of
18 ng/mL for males and 20 ng/mL for females in a cohort of 242 self-
reported cardiac healthy individuals [20]. In contrast, Gaze et al. found
higher values in male individuals compared with female individuals
and reported 97.5th percentile URLs of 33 ng/mL for males and
27 ng/mL for females in a cohort of 627 apparently healthy individuals
[21]. Our present reference value study on 402 healthy blood donors re-
vealed higher values in females comparedwithmales rather supporting
the results of La'ulu et al. [20]. Even the manufacturer describes higher
median galectin-3 concentrations and higher URLs for females com-
pared with males in the package insert of the galectin-3 assay. Our re-
sults of higher galectin-3 concentrations in female individuals are
further supported by previously published data from community
based studies using another galectin-3 assay [24,25]. In our presentevaluation, we found 97.5th percentile URLs of 16 ng/mL for males
and 17 ng/mL for females, which are lower than in both previously pub-
lished reference value studies on theAbbott galectin-3 assay [20,21] and
also lower than the values reported in the package insert.Wewould like
Table 2
Reference values for the cohort of individuals with an eGFR N90 mL/min/1.73 m2 (n = 402).
Analyte Gender Median 25th–75th percentiles 95th percentile URLa 97.5th percentile URLa 99th percentile URLa
Galectin-3 [ng/mL] Male (n = 259) 10.4 9.1–12.1 14.7 (90% CI, 13.9–15.7) 15.8 (90% CI, 14.7–16.1) 16.2
Female (n = 143) 11.6 9.5–13.1 16.2 (90% CI, 15.2–16.9) 16.9 (90% CI, 16.0–21.9) 20.0
hs-cTnI [ng/L] Male (n = 259) 1.9 1.9–2.2 7.1 (90% CI, 4.9–14.8) 16.4 (90% CI, 7.5–36.0) 39.0
Female (n = 143) 1.9 1.9–1.9 4.1 (90% CI, 2.7–14.0) 10.1 (90% CI, 3.9–29.7) 23.5
hs-cTnT [ng/L] Male (n = 259) 5.0 5.0–5.0 7.3 (90% CI, 6.5–9.6) 9.9 (90% CI, 7.3–11.7) 13.9
Female (n = 143) 5.0 5.0–5.0 5.0 (90% CI, 5.0–5.0) 5.0 (90% CI, 5.0–16.1) 11.3
Abbreviations: CI, conﬁdence interval; hs-cTnI, high-sensitivity cardiac troponin I (Abbott); hs-cTnT, high-sensitivity cardiac troponin T (Roche); URL, upper reference limit.
a We followed the Clinical and Laboratory Standards Institute (CLSI) guideline EP28-A3c for estimating right-sided percentiles and their 90% CI. In these guidelines, percentiles are calculated
as the observations corresponding to rank r= p * (n+1). Also for the 90% CI of the reference limits, the CLSI guidelines were followed and conservative CI was calculated using integer ranks
(and therefore the CI is at least 90% wide). No potential outliers were excluded for galectin-3, hs-cTnI or hs-cTnT.
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our stringent exclusion criteria (regarding not only cardiovascular dis-
ease, but also renal disease, diabetes mellitus, cancer, current infection
and chronic inﬂammatory disease; diseases known to be associated
with circulating galectin-3 concentrations). Probably, the situation for
galectin-3 is the same as with, e.g., cardiac troponins, where the refer-
ence population selection strategy (coning) signiﬁcantly inﬂuences
the reference values for troponin assays [8,9,26].
In the past, numerous studies have been published on reference
values for hs-cTnI determined with the “STAT High Sensitive
Troponin-I” assay fromAbbott Diagnostics [9,17,18] and for hs-cTnT de-
terminedwith the “Troponin T hs” assay fromRocheDiagnostics [8,9,18,
19,26]. In principle, our work is conﬁrming the results of previously
published reference value studies on the same assays with respect to
the magnitude of the URLs obtained. Considering that our URLs were
derived without any “outlier” exclusion procedure, we are able to
argue that we had very stringent selection criteria and, thus, rather
low reference values for hs-cTnI andhs-cTnT. Ifwe had, for example, ex-
cluded one “outlier” in our male cohort and one “outlier” in the female
cohort, the 99th percentile URLs would have dropped signiﬁcantly for
hs-cTnI (male, from 39 ng/L to 29 ng/L; female from 24 ng/L to
15 ng/L) and also for hs-cTnT (male, from 14 ng/L to 11 ng/L; female
from 11 ng/L to 5 ng/L). However, as stated in the Results section,
those individuals with hs-cTnI values ≥15 ng/L (n = 8) were different
from those individuals with hs-cTnT values ≥10 ng/L (n=7), indicating
that the substantial increased values produced by both assays in differ-
ent individuals were not real in nature (in the sense of myocardial inju-
ry) but represent non-speciﬁc rises of hs-cTnI or hs-cTnT. This
observation was the reason why we decided not to exclude potential
“outliers” fromour reference value calculation for both analytes. Our ad-
vantage was that we had measured hs-cTnI or hs-cTnT (and also
galectin-3) in a single cohort of healthy individuals. Thus, we complied
with an important requirement recently claimed by several experts in
the ﬁeld [11,12,18,27].
Most importantly, with respect to the “STAT High Sensitive
Troponin-I” assay from Abbott Diagnostics and the “Troponin T hs”
assay from Roche Diagnostics, we found that of the 402 healthy blood
donors, 290 (72%) had hs-cTnI plasma concentrations ≤1.9 ng/L
(i.e., limit of detection of the Abbott assay), and 359 (89%) had hs-
cTnT plasma concentrations ≤5.0 ng/L (i.e., limit of detection of the
Roche assay). Recently, it has been postulated that high-sensitivity as-
says should measure cardiac troponins above the limit of detection in
≥50% of healthy individuals [13,27]. Thus, at least in our reference pop-
ulation both the Abbott hs-cTnI assay and the Roche hs-cTnT assay
failed to comply with this demand.
In conclusion, plasma concentrations of galectin-3, hs-cTnI and hs-
cTnT and corresponding 99th percentile URLswere rather low in our co-
hort of healthy blood donors compared with previously published data.
In our reference population, analyte plasma concentrations above the
limit of detection were detectable in 100% of the individuals with the
Abbott galectin-3 assay, but only in less than 50% for both the Abbott
hs-cTnI assay and the Roche hs-cTnT assay.We acknowledge that hs-cTnT, hs-cTnI and galectin-3 have been
measured in the same cohort but after approximately one, ﬁve and
seven years from sample collection, respectively. At present, there are
no published studies reporting on the long-term in-vitro stability of
galectin-3 and hs-cTnI as measured with the Abbott assays and of hs-
cTnT as measured with the Roche assay at −80 °C. According to the
package inserts and to otherwise published work [21,28–30], however,
in-vitro stabilities of all three analytes stored at ≤−10 °C are evident for
up to several months. Becausewe have subjected frozen aliquots to one
freeze–thaw cycle only as outlined in theMaterials andmethods section
and, thus, met the accepted pre-analytical requirements for frozen sam-
ples, we assume analyte stabilities at−80 °C even for several years.
It might be considered another limitation or ourwork that our refer-
ence value population was mainly composed by young people with a
median individuals' age of 35.0 years (range, 18.0–64.4; 25th–75th per-
centiles, 25.9–45.1). As a consequence, we cannot entirely exclude the
possibility that this might have contributed to the observation that the
tests for hs-cTnI and hs-cTnT did not match the deﬁnition for “high sen-
sitive”. Nevertheless, we saw remarkably increased troponin concentra-
tions predominantly in the younger individuals as shown in Fig. 1, and
because these values did signiﬁcantly contribute to the 99th percentile
URLs of hs-cTnI and hs-cTnT in our work, evaluating rather elderly indi-
viduals might have contributed to lower 99th percentile URLs of both
analytes. Notwithstanding the above, we think that in the case of estab-
lishing reference values for cardiac troponins and other cardiac bio-
markers rigor in subject selection is mandatory. We would like to
suggest that it would be prudent to use highly selected population
groups when performing reference interval studies. Selection criteria
should include a detailed questionnaire and several biomarker mea-
surements (maybe also electrocardiography and echocardiography) to
reliably exclude individuals with any cardiovascular disease, renal dis-
ease and inﬂammatory/infectious disease. With such rigid criteria one
would probably be forced to rely on rather young individuals for a refer-
ence value study.
A last possible limitation deserves also clariﬁcation: According to the
Materials and methods section, the three analytes of interest have been
determined in EDTA plasma samples; according to the package inserts
of Abbott and Roche, galectin-3 hs-cTnI and hs-cTnT concentrations
can be evaluated in both EDTA plasma and serum. However, according
to a recent publication [19], slight but signiﬁcantly different values
may be obtained measuring hs-cTnI in heparin plasma vs. EDTA plasma
or serum. In this publication, the slopes and intercepts obtained for
serum vs. lithium heparin and for EDTA vs. lithium heparin were ap-
proximately 1.15 and b0.5 ng/L, respectively, by Passing Bablok but
not signiﬁcantly different by Bland–Altman and, thus, can be considered
negligible for clinical practice.
Conﬂict of interest statement
Author's conﬂict of interest disclosure: Abbott Diagnostics and Roche
Diagnostics provided reagents for measurement of hs-cTnI and hs-
cTnT plasma concentrations, respectively, free of charge. The companies
23T. Mueller et al. / Clinica Chimica Acta 456 (2016) 19–23(1) did not play a role in the study design; (2) in the collection, analysis,
and interpretation of data; (3) in writing of the report; (4) or in the de-
cision to submit the report for publication.
Research funding: None declared.
Employment or leadership: None declared.
Honoraria: Thomas Mueller has received speaking fees from Abbott
Diagnostics, B.R.A.H.M.S. AG, and Roche Diagnostics. Benjamin
Dieplinger has received speaking fees from Abbott Diagnostics and
Roche Diagnostics.
Nonstandard abbreviations
BNP B-type natriuretic peptide
CI conﬁdence interval
CRP C-reactive protein
eGFR estimated glomerular ﬁltration rate
hs-cTnI high-sensitivity cardiac troponin I
hs-cTnT high-sensitivity cardiac troponin T
IL-6 interleukin-6
PCT procalcitonin
URL upper reference limit
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